Heat Biologics Company Profile (NASDAQ:HTBX)

About Heat Biologics

Heat Biologics logoHeat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HTBX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.80
  • 50 Day Moving Average: $0.9376
  • 200 Day Moving Average: $1.2507
  • 52-Week Range: $0.40 - $3.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.17
  • P/E Growth: 0.0000
  • Market Cap: $19.22M
  • Outstanding Shares: 23,883,000
  • Beta: 0.93
Profitability:
  • Return on Equity: -516.63%
  • Return on Assets: -147.96%
Debt:
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.71%
  • Quick Ratio: 2.71%
Additional Links:
Companies Related to Heat Biologics:

Analyst Ratings

Consensus Ratings for Heat Biologics (NASDAQ:HTBX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (521.20% upside)

Analysts' Ratings History for Heat Biologics (NASDAQ:HTBX)
Show:
DateFirmActionRatingPrice TargetDetails
12/8/2016Roth CapitalSet Price TargetBuy$2.00View Rating Details
8/17/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details
4/9/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details
2/21/2016HC WainwrightReiterated RatingBuy$13.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Heat Biologics (NASDAQ:HTBX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2016        
11/10/2016Q3 2016($0.15)($0.08)ViewN/AView Earnings Details
8/15/2016Q2($0.27)($0.17)ViewN/AView Earnings Details
5/11/2016Q1($0.56)($0.50)ViewN/AView Earnings Details
2/18/2016Q4($0.64)($0.78)ViewN/AView Earnings Details
10/30/2015Q3($0.61)($0.62)ViewN/AView Earnings Details
8/13/2015Q2($0.47)($0.56)ViewN/AView Earnings Details
5/14/2015Q1($0.49)($0.57)ViewN/AView Earnings Details
4/16/2015($0.49)($0.56)ViewN/AView Earnings Details
3/27/2015($0.44)($0.56)ViewN/AView Earnings Details
11/14/2014Q314($0.42)($0.46)ViewN/AView Earnings Details
8/14/2014Q214($0.40)($0.44)ViewN/AView Earnings Details
5/14/2014($0.38)($0.36)ViewN/AView Earnings Details
4/1/2014($0.30)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Heat Biologics (NASDAQ:HTBX)
Current Year EPS Consensus Estimate: $-0.6600 EPS
Next Year EPS Consensus Estimate: $-0.6900 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.16)($0.16)($0.16)
Q4 20161($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Heat Biologics (NASDAQ:HTBX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Heat Biologics (NASDAQ:HTBX)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 1.78%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/23/2016Michael KharitonovDirectorBuy900,000$0.75$675,000.00View SEC Filing  
5/19/2014Jeffrey Alan WolfCEOBuy2,500$4.13$10,325.00View SEC Filing  
5/16/2014Paul BelskyDirectorBuy2,500$4.11$10,275.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Heat Biologics (NASDAQ:HTBX)
DateHeadline
News IconAnalyst Views On Top Movers In Recent Trade: Heat Biologics, Inc. (HTBX), Southwestern Energy Company (SWN) - Post Analyst (NASDAQ:HTBX)
postanalyst.com - February 24 at 7:02 PM
News IconHeat Biologics, Inc. (NASDAQ:HTBX) Projected to Achieve EPS Of ... - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - February 23 at 10:46 PM
News IconHeat Biologics, Inc. (HTBX): Important Trade and Target Levels To Watch - Post Analyst (NASDAQ:HTBX)
postanalyst.com - February 22 at 5:55 PM
News IconHeat Biologics Inc (NASDAQ:HTBX) Unveils Its Immune Data At Genitourinary Cancers Symposium - Traders350 (NASDAQ:HTBX)
traders350.com - February 22 at 5:54 PM
bizjournals.com logoHeat Biologics offers further bladder cancer treatment outlook (NASDAQ:HTBX)
www.bizjournals.com - February 22 at 12:46 PM
News IconTop Institutional Investors That Own Heat Biologics, Inc. (HTBX) - Post Analyst (NASDAQ:HTBX)
postanalyst.com - February 19 at 10:26 AM
News IconABR Of Heat Biologics, Inc. (NASDAQ:HTBX) Stock At 1 - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - February 19 at 10:26 AM
4-traders.com logoU S Bureau of Census : New Advance Quarterly Services Report (NASDAQ:HTBX)
www.4-traders.com - February 18 at 5:12 PM
finance.yahoo.com logoHeat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium (NASDAQ:HTBX)
finance.yahoo.com - February 17 at 8:36 AM
finance.yahoo.com logo7:02 am Heat Biologics presents data from its Phase 2 trial evaluating vesigenurtacel-L (HS-410) either alone or in combination with BCG in patients with non-muscle invasive bladder cancer at the GU Cancers Symposium (NASDAQ:HTBX)
finance.yahoo.com - February 17 at 8:36 AM
4-traders.com logoCEL SCI : Research Reports Initiation on Biotech Stocks -- Heat Biologics, PDL BioPharma, Achaogen, and CEL-SCI (NASDAQ:HTBX)
www.4-traders.com - February 16 at 5:40 PM
finance.yahoo.com logoHeat Biologics to Present at the Genitourinary Cancers Symposium (NASDAQ:HTBX)
finance.yahoo.com - February 14 at 7:07 PM
News IconTechnical Levels in Review on Shares of Heat Biologics Inc. (HTBX) - Davidson Register (NASDAQ:HTBX)
davidsonregister.com - February 10 at 11:32 PM
News IconHeat Biologics Inc HTBX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:HTBX)
www.bioportfolio.com - February 5 at 5:31 PM
News IconHeat Biologics, Inc. (NASDAQ:HTBX) Analytical Analysis - The Newburgh Press (NASDAQ:HTBX)
newburghpress.com - February 4 at 5:48 PM
News IconHeat Biologics, Inc. (NASDAQ:HTBX) Projected EPS At $-0.07 ... - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - February 3 at 4:29 AM
News IconNotable Stock For Under $5: Heat Biologics, Inc. (NASDAQ:HTBX) - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - February 1 at 6:27 AM
News IconUnder the Microscope We Place Shares of Heat Biologics, Inc. (NASDAQ:HTBX) - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - February 1 at 6:27 AM
News IconNoble Corporation (NE) Upgraded to "Buy" by Jefferies Group LLC (NASDAQ:HTBX)
larampadinapoli.com - January 30 at 11:31 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Heat Biologics, Inc. (NASDAQ:HTBX) - Nelson Research (NASDAQ:HTBX)
nelsonobserver.com - January 29 at 4:14 AM
News IconSleepy Friday? Not For This Active Stock: Heat Biologics, Inc. (NASDAQ:HTBX) - Wall Street Beacon (NASDAQ:HTBX)
wsbeacon.com - January 28 at 12:58 AM
News IconUnorthodox Volume Noted Mid-Session in Shares of Heat Biologics, Inc. (NASDAQ:HTBX) - Aiken Advocate (NASDAQ:HTBX)
aikenadvocate.com - January 27 at 7:44 PM
News IconUnorthodox Volume Noted Mid-Session in Shares of Heat Biologics ... - Aiken Advocate (NASDAQ:HTBX)
aikenadvocate.com - January 27 at 7:44 PM
News IconADX Watch on Shares of Heat Biologics Inc. (HTBX) - Sherwood Daily (NASDAQ:HTBX)
sherwooddaily.com - January 27 at 7:43 PM
News IconSleepy Friday? Not For This Active Stock: Heat Biologics, Inc ... - Wall Street Beacon (NASDAQ:HTBX)
wsbeacon.com - January 27 at 7:43 PM
News IconMarket Rover: Looking at Levels on Shares of Heat Biologics Inc. (HTBX) - Sherwood Daily (NASDAQ:HTBX)
sherwooddaily.com - January 26 at 7:24 PM
News IconHeat Biologics, Inc. (NASDAQ:HTBX) Projected EPS At $-0.07 - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - January 26 at 7:23 PM
News IconIs this Stock Under $5 a Bargain: Heat Biologics, Inc. (NASDAQ:HTBX) - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - January 26 at 1:19 AM
News IconFocus on RSI and CCI Levels: Heat Biologics Inc. (HTBX) - Sherwood Daily (NASDAQ:HTBX)
sherwooddaily.com - January 25 at 3:17 PM
finance.yahoo.com logoHeat Biologics to Present at NobleCon13 (NASDAQ:HTBX)
finance.yahoo.com - January 24 at 6:30 PM
News IconTrading Scope: Indicator Review for Heat Biologics Inc. (HTBX) - Sherwood Daily (NASDAQ:HTBX)
sherwooddaily.com - January 20 at 12:34 AM
News IconHeat Biologics Inc (NASDAQ:HTBX) Just Signed One Of Peregrine Pharmaceuticals (NASDAQ:PPHM)'s Top Guys - Insider Financial (NASDAQ:HTBX)
www.insiderfinancial.com - January 20 at 12:34 AM
News IconStock ABR Heat Biologics, Inc. (NASDAQ:HTBX) At 1 - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - January 16 at 5:44 PM
News IconAre There Any Catalysts to Propel This Stock Forward: Heat Biologics, Inc. (NASDAQ:HTBX) - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - January 12 at 11:17 PM
News IconHeat Biologics, Inc. (NASDAQ:HTBX) Insider Ownership stands at 30.02 - The Newburgh Press (NASDAQ:HTBX)
newburghpress.com - January 12 at 11:17 PM
seekingalpha.com logoHeat Biologics (HTBX) Presents At 9th Annual Biotech Showcase 2017 Conference (NASDAQ:HTBX)
seekingalpha.com - January 12 at 6:16 PM
marketexclusive.com logoHeat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Regulation FD Disclosure (NASDAQ:HTBX)
marketexclusive.com - January 9 at 6:28 PM
News IconStock ABR Of Heat Biologics, Inc. (NASDAQ:HTBX) At 1 - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - January 8 at 12:39 AM
News IconProjected EPS Of Heat Biologics, Inc. (NASDAQ:HTBX) At $-0.07 - Stock Observer (NASDAQ:HTBX)
www.thestockobserver.com - January 6 at 11:24 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:HTBX)
biz.yahoo.com - January 6 at 6:23 PM
News IconAstute Investors Are Taking a Look at Heat Biologics, Inc. (NASDAQ:HTBX) - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - January 6 at 5:01 AM
finance.yahoo.com logoHeat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco (NASDAQ:HTBX)
finance.yahoo.com - January 5 at 6:58 PM
News IconTrick or Treat? Iconic Brands Inc (OTCMKTS: ICNB) has produced profits of over 17,900 % in portfolios since Halloween 2016! (NASDAQ:HTBX)
streetregister.com - January 5 at 6:25 AM
publicnow.com logoHeat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer (NASDAQ:HTBX)
www.publicnow.com - January 4 at 4:49 PM
biz.yahoo.com logoHEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defini (NASDAQ:HTBX)
biz.yahoo.com - January 4 at 4:49 PM
News IconInvestors Swarm in on Heat Biologics, Inc. (NASDAQ:HTBX ... - Prospect Journal (NASDAQ:HTBX)
prospectjournal.com - January 3 at 8:33 PM
News IconThe Heat Biologics Inc (NASDAQ:HTBX)
myhealthbowl.com - December 22 at 6:04 PM
News IconHeat Biologics Inc (NASDAQ:HTBX) Is Undervalued (NASDAQ:HTBX)
streetregister.com - December 21 at 6:37 PM
marketexclusive.com logoHeat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Termination of a Material Definitive Agreement (NASDAQ:HTBX)
marketexclusive.com - December 11 at 10:31 AM
smarteranalyst.com logoRoth Capital Sees Over 100% Upside for Heat Biologics Inc (HTBX) as the Stock Continues to Struggle (NASDAQ:HTBX)
www.smarteranalyst.com - December 9 at 10:57 PM

Social

What is Heat Biologics' stock symbol?

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Where is Heat Biologics' stock going? Where will Heat Biologics' stock price be in 2017?

3 brokers have issued 12-month target prices for Heat Biologics' shares. Their predictions range from $2.00 to $8.00. On average, they expect Heat Biologics' share price to reach $5.00 in the next twelve months.

When will Heat Biologics announce their earnings?

Heat Biologics is scheduled to release their next quarterly earnings announcement on Monday, October, 31st 2016.

Who owns Heat Biologics stock?

Heat Biologics' stock is owned by many different of retail and institutional investors. Top institutional investors include Oxford Asset Management (1.34%).

Who bought Heat Biologics stock? Who is buying Heat Biologics stock?

Heat Biologics' stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management.

How do I buy Heat Biologics stock?

Shares of Heat Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Heat Biologics stock cost?

One share of Heat Biologics stock can currently be purchased for approximately $0.80.

Heat Biologics (NASDAQ:HTBX) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Heat Biologics (NASDAQ:HTBX)

Earnings History Chart

Earnings by Quarter for Heat Biologics (NASDAQ:HTBX)

Dividend History Chart

Dividend Payments by Quarter for Heat Biologics (NASDAQ:HTBX)

Last Updated on 2/25/2017 by MarketBeat.com Staff